At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 enrolled
Drug / intervention
LY3526318 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
In Brief
A Phase 2 clinical trial evaluating LY3526318 and Placebo for Diabetic Peripheral Neuropathic Pain. Completed, enrolled 155 participants across 37 sites in 2 countries.
Detailed Summary
The purpose of this study is to test the safety and efficacy of study drug LY3526318 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Peripheral Neuropathic Pain
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartJan 2022
Primary CompletionOct 2022
TodayJul 2026
First PostedJan 4, 2022
Enrollment StartJan 26, 2022
Primary CompletionOct 13, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.5 years ago
Interventions
LY3526318drug
Administered orally
Placebodrug
Administered orally